ArticleInfection control and hospital epidemiology2022
"Original antigenic sin": A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants.
Article in Infection control and hospital epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.Reviews in medical virology · 2022Pooled it
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- Trial
- Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin.Nature communications · 2024Article
- Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine.NPJ vaccines · 2024Article
- Investigating the Antibody Imprinting Hypothesis among Canadian Paramedics after SARS-CoV-2 Omicron Variant Circulation.ImmunoHorizons · 2024Article
- COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.Cureus · 2024Review
- Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain.Pathogens (Basel, Switzerland) · 2023Article
- Review
- Novel coronavirus mutations: Vaccine development and challenges.Microbial pathogenesis · 2022Review
- Article
- Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review.Medicina (Kaunas, Lithuania) · 2022Review
- Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.Vaccines · 2022Review
- [Possible effect of the "original antigenic sin" in vaccination against new variants of SARS-CoV-2].Revista clinica espanola · 2022Article
- SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.Cell reports · 2022Article
- SARS-CoV-2 Spike Protein Vaccine-Induced Immune Imprinting Reduces Nucleocapsid Protein Antibody Response in SARS-CoV-2 Infection.Journal of immunology research · 2022Article
- The "original antigenic sin" and its relevance for SARS-CoV-2 (COVID-19) vaccination.Clinical immunology communications · 2021Review
- Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.Nature reviews. Immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.